SCHEMBL6709683

SCHEMBL6709683

NC(=O)c1ccc(N2CCN(C(=O)c3ccc(Cl)s3)CC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.71
ALDH1A1 P00352 5/20 0.58
HPGD P15428 1/20 0.58
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
LMNA P02545 6/20 0.51
HTT P42858 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PARP14 Q460N5 3/20 0.50
PARP10 Q53GL7 3/20 0.50
F2 P00734 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
TSHR P16473 1/20 0.48
HSP90AA1 P07900 1/20 0.48
TP53 P04637 1/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709685 0.86 MAPT (0.75) MAPTALDH1A1HPGDCA12CA1
SCHEMBL20460413 0.74 HPGD (0.96) MAPTALDH1A1HPGDCA12CA1
SCHEMBL3276407 0.73 MEN1 (0.74) MAPTALDH1A1CA12CA1CA2
SCHEMBL4985313 0.72 GFER (0.70) MAPTALDH1A1HPGDHTTPARP14
SCHEMBL13437944 0.72 HRH3 (0.58) MAPTALDH1A1HPGDKMT2AMEN1
SCHEMBL3637388 0.72 TDP1 (0.69) MAPTALDH1A1HPGDCA12CA1
SCHEMBL4989513 0.72 CHRNA7 (0.58) MAPTALDH1A1KMT2ACHRNA7CHRNA10
SCHEMBL4985730 0.71 AKR1C3 (0.64) MAPTALDH1A1HPGDLMNAHTT
SCHEMBL30876047 0.71 HPGD (0.73) MAPTALDH1A1HPGDCA12CA1
SCHEMBL27524146 0.71 HPGD (0.73) MAPTALDH1A1HPGDCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same PIERRE FABRE MEDICAMENT (FR) 2004-05-13 US disclosed
EP-1324999-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2003-07-09 EP disclosed
WO-2002030927-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same CBR3, CBR1, HCCS MAPT 4753/4885ALDH1A1 3031/4885HPGD 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.